Investors who have invested in the fund believe that it has been very difficult recently because the fund is also facing a sharp decline, especially in the new energy sector and the medical sector. Moreover, the fund's plunge was also found. In fact, the current sharp decline in medical care did not occur during this period. This has been the case since last year. At the beginning, the sharp decline in medical care was mainly due to the sharp decline of the leading drug Wuxi PharmaTech. This is also because some countries have suppressed China's medical enterprises, which has led to a sharp decline. In Bian Xiao's view, it is not unusual for the pharmaceutical sector to plummet, leading to such a tragic decline in the pharmaceutical fund. In fact, I still think that the economy has been declining because of the epidemic. Although the economy has recovered, its performance is far less than expected. At the same time, the increase in the early stage of medicine is too large, and the valuation of the callback will be higher. In the face of this situation, it is normal to have a decline.

Medicine has fallen so badly, is there any chance in the later stage?

In fact, there will still be some opportunities in the future, as Bian Xiao thinks, because medicine will still have room for decline in a short time. However, considering the overall situation in China, because we will face an aging trend at present, which is also a long-term basic national condition, we will spend more on medical care and medicine in the future, so medicine will still rise in the long run. In addition, because of the epidemic situation, the status of medical care is very important, and everyone is very optimistic about the medical industry, so it is still of great investment value in the long run.

How to invest in medical care?

Although in the long run, medical care is still very promising, but investment should be cautious. Investment funds should be selected according to our actual situation. If friends who already hold medical funds can bear this decline, they can continue to exist, and at the same time, they can increase their positions to balance the risks when they plummet. However, it is best not to open positions immediately, and they can invest appropriately.

abstract

Finally, according to the whole market situation, we need to wait for some more observations on the position management of pharmaceutical funds, so as to ensure that losses can be avoided.